Coagulation, COVID-19, Hemostasis
Conditions
Keywords
COVID-19, venous ultrasound, Hemostasis, coagulation
Brief summary
The understanding of haemostasis and inflammation cross-talk has gained considerable knowledge during the past decade in the field of arterial and venous thrombosis. Complex and delicately balanced interaction between coagulation and inflammation involve all cellular and humoral components. Elements of the coagulation system such as activated thrombin, fibrinogen or factor Xa may increase inflammation by promoting the production of proinflammatory cytokines, chemokines, growth factors and adhesion molecules that lead to a procoagulant state amplifying the pathological process. Recent evidence supports inflammation as a common pathogenic contributor to both arterial and venous thrombosis, giving rise to the concept of inflammation induced thrombosis. Patients with infection of COVID-19 and severe pneumoniae seem to have higher risk of thromboembolism. The purpose of this project is to analyze hemostasis and coagulation of every hospitalized patient with infection of COVID-19. Blood sample for coagulation and hemostasis analysis will be collected on every patient hospitalized in Amiens hospital for COVID-19 infection. Thrombin time, factors V and II, fibrin/fibrinogen degradation products, antithrombin will be assessed every week. Anticardiolipin, anti-beta2 glycoprotein I and anti-annexin A2 antibodies IgG and IgM at day of admission and at fourth week after admission will be assessed. SARS-CoV2 viral load and serodiagnosis will be performed at the same time. At the same time venous ultrasound to diagnose thrombosis will be performed.
Interventions
OTHERvenous ultrasound
Venous ultrasound will be performed on patients once a week, every week from the day of admission in Amiens Hospital until the day of patient discharge
BIOLOGICALblood sample
blood sample for coagulation and hemostasis analysis will be withdrawn from artery catheter from the day of admission in Amiens Hospital until the day of patient discharge
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* all patients hospitalized in Amiens Hospital with COVID-19 infection
Exclusion criteria
* patients\< 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients | up to 6 weeks | Variation of thrombin time (in secondes) in Hospitalized Covid-19 patients. The reference range for the thrombin time is usually less than 20 seconds (ie, 15-19 seconds) |
| Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients. | up to 6 weeks | Variation of factor V concentration (U/dL) in Hospitalized Covid-19 patients. |
| Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients | up to 6 weeks | Variation of factor II concentration (U/dL) in Hospitalized Covid-19 patients |
| Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Hospitalized Covid-19 patients. | up to 6 weeks | Variation of concentration of fibrin and fibrinogen degradation products (≥ 10 µgm/mL) in Hospitalized Covid-19 patients. |
Countries
France
Contacts
Primary ContactMichel Slama, Pr
Outcome results
None listed